pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·4d ago·1 min read
save

Marrow extracts $120M series B to advance preclinical blood disease therapy

Nov 13, 2026·read at Fierce Biotech ↗

A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta thalassemia.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 10h agoLilly signs $5.9B deal with Stipple to unlock oncology targetsFierce Biotech
  • 18h agoSellas marks 9-month survival benefit in late-stage leukemia vaccine studyFierce Biotech
  • 1d agoCG preps new, expanded bladder cancer plans with FDA after ph. 3 winFierce Biotech
  • 1d agoBiogen inks $411M neurodegeneration pact with protein degrader biotech TrimTechFierce Biotech
  • 1d agoHelus' chemically modified psychedelic hits key goals in phase 3 depression trialFierce Biotech